DWTX Stock — Dogwood Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.69

Market cap

$57.4M

Cash

$9.6M

Enterprise value

$47.8M

Balance sheet

Cash	$9.6M
Debt	$0.0M
Net cash	$9.6M
Enterprise value	$47.8M
Basic shares	33.6M shares
Fully diluted shares	40.2M shares
Fully diluted market cap	$68.0M
Cash per share	$0.29

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading DWTX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Sep 23, 2026	Halneuron	Phase 2	Chemotherapy Induced Neuropathic Pain; Chemotherapy Induced Pain Neuropathy; Chemotherapy Induced Pain	fall of 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Halneuron

Phase 2 · Active Modality: small molecule (voltage-gated sodium channel inhibitor; highly purified tetrodotoxin)

Target NaV 1.7

Indications

Chemotherapy-induced neuropathic pain (CINP) (Phase 2)

Catalysts

— 2H 2026

Status note Phase 2b HAL-CINP-203 ongoing for CINP; FDA Fast Track designation for CINP. Company developing synthetically manufactured TTX for Phase 3 (2027) with FDA engagement planned 2H 2026. Potential expansion into non-neuropathic cancer pain and acute post-surgical pain. Going-concern warning: cash funds operations only into Q4 2026.

SP16

Preclinical · Active Modality: peptide (17 amino acid, IV formulation)

Target LRP1

Partnerships Serpin Pharma Inc./Rejuvenation Labs: royalty-free global license (equity consideration; expensed as acquired IPR&D)

Indications

Chemotherapy-induced peripheral neuropathy (CIPN) (Phase 1)

Catalysts

— 2H 2026

Status note First-in-class LRP1 agonist. FDA accepted IND for IV SP16 for CINP; Phase 1b safety evaluation in cancer patients funded by an NCI grant (no expense to company), recruitment/dosing expected 2H 2026.

IMC-1

Stage not disclosed · Active Modality: small molecule (fixed-dose combination of a nucleoside analog and celecoxib)

Partnerships PRIDCor Therapeutics: exclusive global license; PRIDCor funds all development (tiered royalties up to 15%, 10% of Series A, 9% of future raises, payments capped at $100M; $100,000 first payment received July 2026)

Indications

Fibromyalgia (Stage not disclosed)

Status note Partnered out-licensed program; company has no further R&D or marketing obligations. Proceeds above $100K subject to CVR pass-through (87.75% to CVR holders).

IMC-2

Stage not disclosed · Active Modality: small molecule (combination of valacyclovir and celecoxib)

Partnerships PRIDCor Therapeutics: exclusive global license (same terms as IMC-1)

Indications

Long-COVID (Stage not disclosed)

Status note Partnered out-licensed program; company has no further R&D or marketing obligations.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Halneuron
Lead indication	Chemotherapy Induced Neuropathic Pain
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06848348	Phase 2	Recruiting	Sponsor	DWTX	—	Chemotherapy Induced Neuropathic Pain; Chemotherapy Induced Pain Neuropathy; Chemotherapy Induced Pain	fall of 2026

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Dogwood Therapeutics Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

DWTX — Dogwood Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials